OPTIMIZING THE TREATMENT EXPERIENCE FOR CHILDREN WITH JIA AND OTHER AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS
ROS Therapeutics is a development stage pharmaceutical company committed to optimize the treatment experience and address unmet needs of children with Juvenile Idiopathic Arthritis (JIA) and other autoimmune and chronic inflammatory conditions through an innovative proprietary best-in-class orally delivered methotrexate therapy; Trexior™.
Methotrexate (MTX) is a cornerstone treatment for JIA, one of the most common childhood diseases as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults.
Since the early 90’ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies.
Several of the shortcomings of existing
methotrexate therapies, whether oral or injections, are sought overcome with Trexior.
March 01, 2021
October 5, 2020
July 01, 2021
June 01, 2022
September 20, 2022
ROS Therapeutics ApS, Ole Maaløes vej 3, 2200 Copenhagen N, Denmark